



DAY 1 THURSDAY - JANUARY 29, 2015		
2:00-2:10	Welcome and introduction	F. Foss
2:10-2:15	Introduction of keynote presenter	E. Jaffe
2:15-3:00	Keynote address: Clinical Research on T-cell Lymphoma in Japan	K. Tobinai
SESSION 1: Molecular Pathogenesis		
Moderators:	E. Jaffe, Y. Shi	
3:00-3:15	The role of IDH2 mutations in T-cell Lymphoma: Is it really restricted to AITL?	T. Mak
3:15-3:30	Understanding the molecular pathogenesis of the sezary syndrome	P. Porcu
3:30-3:45	Mutations in DNMT3 in PTCL: Implications for a tailored therapeutic strategy	L. Couronne
3:45-4:00	Discrimination of mutations arising in pre-malignant cells and those in lymphoma cells in AITL	M. Sakata-Yanagimoto
4:00-4:15	Molecular heterogeneity of ALK-negative ALCL	A.L. Feldman
4:15-4:30	Panel Discussion	
4:30-4:45	Break	
SESSION 2: Global epidemiology of T-cell lymphoma		
Moderators:	M. Federico, HQ Huang	
4:45-5:00	Histopathology: Major discussing points for the next WHO classification of PTCL	E. Jaffe
5:00-5:15	T-cell lymphomas in South America	C. Chiattonne
5:15-5:30	Incidence and frequencies of T/NK-cell lymphoma subtypes in American Indian/Alaska Native peoples	A. Shustov
5:30-5:45	Differences in incidence and trends of lymphoma, especially PTCL and ATL, in Japan and the United States	D. Chihara
5:45-6:00	Panel Discussion	
6:15-10:00	Welcome Dinner	

DAY 2 FRIDAY - JANUARY 30, 2015		
7:00-8:00am	Continental Breakfast	
8:00-8:05	Day 2 opening remarks:	O. O'Connor
SESSION 3: Biological Therapies of T-cell lymphoma		
Moderators:	S. Bates, O. O'Connor	
8:05-8:20	Epigenetic therapy of T/NK-cell lymphoma	H. Kimura
8:20-8:35	PD-1 and its role in T cell lymphoma	H. Kohrt
8:35-8:50	Anti-viral approaches for the management of ATL	O. Hermine
8:50-9:05	Tax-specific T-cell responses in allo-HSCT for ATL	A. Hasegawa
9:05-9:20	Chidamide, a new HDAC inhibitor, for PTCL	Y. Shi
9:20-9:35	Panel Discussion	
9:30-9:45	Break	
SESSION 4: Novel Drug Combination in T-cell Lymphoma		
Moderators:	F. Foss, H. Kimura	
9:45-10:00	Building novel combination therapies in PTCL: Moving beyond the single agents	O. O'Connor
10:00-10:15	Combination therapies: Lessons from molecularly defined solid tumor models	S. Bates
10:15-10:30	Preclinical rationale for alisertib – romidepsin combinations	M. Fanale

**** AGENDA IS NOT FINAL AND SUBJECT TO CHANGE ****

BOLDED NAMES HAVE BEEN CONFIRMED.



10:30-10:45	What is the role of chemotherapy in the era of biological agents in the treatment of cutaneous T cell lymphoma?	M. Prince
10:45-11:00	Making the case for novel combinations as the future in PTCL	PL Zinzani
11:00-11:15	Brentuximab combinations: What does the future hold?	S. Ansell
11:15-11:30	Is there a potential for bendamustine to replace CHOP in T-cell lymphoma?	B. Coiffier
11:30-11:45	Panel Discussion	
12:00-1:40	Lunch Symposium: Evolving Treatment Approaches in Peripheral T-cell Lymphoma	
SESSION 5: Conundrums in PTCL Management		
Moderators:	K. Tobinai, S. Horwitz	
1:45-2:00	Should we ever consider allogeneic stem cell transplant in first remission?	S. Smith
2:00-2:15	γδ T-cell lymphoma	F. Foss
2:15-2:30	Should CNS prophylaxis be a matter of routine in PTCL?	B. Pro
2:30-2:45	Panel Discussion	
SESSION 6: Clinical Topics		
Moderators:	PL Zinzani, M. Prince	
2:45-3:00	Newer agents in CTCL	M. Duvic
3:00-3:15	Emerging trends in the treatment of nasal NK/T cell lymphoma	W S Kim
3:15-3:30	Circulating EBV DNA in NK/T-cell lymphoma	Y.L. Kwong
3:30-3:45	Role of PET/CT in the management of T/NK-cell lymphoma	HQ Huang
3:45-4:00	Extranodal variants of ATL	K. Tsukasaki
4:00-4:15	Panel Discussion	
4:15-4:30	Break	
SESSION 7: Poster presentations		
Moderators:	F. Foss, O. O'Connor, K. Tobinai	
4:30-4:40	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation	P. Staber
4:40-4:50	Defining characteristics of T-memory cells and dendritic cells in the CTCL microenvironment	C. Querfeld
4:50-5:00	FoxP3-positive T-cell lymphoma arising in non-HTLV1 carrier: Clinicopathological analysis of 11 cases of PTCL-NOS and 2 cases of mycosis fungoides	A. Satou
5:00-5:10	T cell lymphomas in Jordan	A. Addasi
5:10-5:20	Excellent non clinical safety profile of IPH4102, the first anti-KIR3DL2 mAb for the treatment of CTCL	H. Sicard
5:20-5:30	A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation	T. Waldmann
5:30-5:40	European phase 2 study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral T-cell lymphoma(PTCL)	PL. Zinzani
5:40-5:50	Final analysis of the Ro-CHOP phase Ib/II study: Romidepsin in association with CHOP in untreated patients with peripheral T-cell lymphoma (PTCL)	B. Coiffier
5:50-6:00	Incidence of CNS disease in peripheral T-cell lymphomas: Retrospective analysis from a single north American institution	R. Safyan
6:00-8:00	Poster Walk Reception	



DAY 3 SATURDAY - JANUARY 31, 2015		
7:00-8:00am	Breakfast Symposium: TBD	
8:10-8:15am	Day 3 opening remarks:	K. Tobinai
SESSION 8: Improving treatment strategies in PTCL and CTCL		
Moderators:	M. Duvic, B. Pro	
8:15-8:30	T-cell Project update	M. Federico
8:30-8:45	Denileukin diftitox: Changing landscape and utility in CTCL	Y. Kim
8:45-9:00	Survival of patients with relapsed or refractory PTCL based on the database in British Columbia	K. Savage
9:00-9:15	Developing a treatment algorithm for relapsed PTCL: How to incorporate new drugs	S. Horwitz
9:15-9:30	Is watch and wait still standard for indolent ATL?	K. Ishitsuka
9:30-9:45	Current issues and new trends in allogeneic SCT for ATL	T. Fukushima
9:45-10:00	Panel Discussion	
10:00-10:15	Break	
SESSION 9: The industry's perspective		
Moderators: F. Foss, O. O'Connor, K. Tobinai		
10:15-10:30	Exportin inhibitors	S. Shacham, Karyopharm
10:30-10:45	IMiDs	K. Foon, Celgene
10:45-11:00	IDH1/2 inhibitors	C. Bowden, Agios
11:00-11:15	PI3 kinase inhibitors	J. Adams, Infinity
11:15-11:45	Discussion	
11:45-11:50	Closing remarks	O. O'Connor
11:50	Adjourn—Box Lunch	